Results 171 to 180 of about 3,543,538 (259)

Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency. [PDF]

open access: yesLiver Cancer, 2019
Yokomichi N   +15 more
europepmc   +1 more source

Aniridia‐associated keratopathy: Clinical and molecular mechanisms of disease progression and emerging therapeutic targets

open access: yesActa Ophthalmologica, EarlyView.
Abstract Congenital aniridia is a rare genetic disorder primarily caused by pathogenic variants of the PAX6 gene. It leads to various panocular anomalies, including aniridia‐associated keratopathy (AAK). This review highlights recent insights into its pathogenesis, focusing on clinical staging, microstructural changes in the cornea and molecular ...
N. Szentmáry   +27 more
wiley   +1 more source

Hair Degradation Patterns in Aquatic and Soil Environments

open access: yesArchaeometry, EarlyView.
ABSTRACT Hair is a biological material that can provide information in archaeology and forensics. Previous studies have mainly examined changes occurring post‐mortem. In this study, we focused on hair pulled out ante‐mortem. The aim of the study was to identify patterns in the degradation of hair in water and soil.
Katarzyna Palacz‐Ziółek   +3 more
wiley   +1 more source

Cellular characteristics of keratin 19-positive canine hepatocellular tumours explain its aggressive behaviour. [PDF]

open access: yesVet Rec Open, 2017
van Sprundel RG   +6 more
europepmc   +1 more source

A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy

open access: yesBJU International, Volume 135, Issue 4, Page 648-656, April 2025.
Objective To further evaluate a genomic classifier (GC) in a cohort of patients undergoing radical cystectomy (RC), as long non‐coding RNA (lncRNA)‐based genomic profiling has suggested utility in identifying a distinct tumour subgroup corresponding to a favourable prognosis in patients with bladder cancer.
Joep J. de Jong   +14 more
wiley   +1 more source

Shared and specific molecular mechanisms of proteasome inhibitors in chemotherapy‐induced peripheral neurotoxicity

open access: yesBritish Journal of Pharmacology, EarlyView.
This study compares the molecular mechanisms of chemotherapy‐related peripheral neurotoxicity of two proteasome inhibitors, bortezomib and carfilzomib, using a multidisciplinary approach to reveal that, alongside shared effects on mitochondria structure and function, the more neurotoxic drug BTZ has specific effects on microtubules and mitochondrial ...
Federico Iseppon   +27 more
wiley   +1 more source

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

Keratin staining of bronchus epithelium (human, adult)

open access: yes, 2006
Stain: Anti-keratin-5-7-14-19 (OVTL 12/5 monoclonal antibody with immunoperoxidase staining on frozen sections). The pseudostratified epithelium (1) is stained keratin-positively (brown product) as well as the epithelial derivates such as the bronchial ...
Poels, Lambert G.
core  

Epithelial YPEL3 Modulates CD8+ T‐Cell Infiltration and Tumor Progression Through CREB1–CXCL16 Signaling in HNSCC

open access: yesCancer Science, EarlyView.
YPEL3 functions as a tumor suppressor in HNSCC by inhibiting tumor progression and promoting apoptosis. Mechanistically, it enhances epithelial–immune crosstalk through the CREB1‐mediated CXCL16–CXCR6 axis, facilitating CD8+ T‐cell infiltration and highlighting its potential as a prognostic biomarker and immunotherapy target.
Yalun Li   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy